Huntsman Cancer Institute adds second Mevion S250i proton therapy system

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Huntsman Cancer Institute at the University of Utah signed a contract with Mevion Medical Systems for a second MEVION S250i Proton Therapy System, doubling treatment capacity and broadening access to patients with a wide range of cancers, including pediatric, head and neck, and breast cancers. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

According to preliminary data from a multi-institution phase III trial led by researchers at MD Anderson Cancer Center, intensity modulated proton therapy achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy as part of chemoradiation treatment for patients with oropharyngeal cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login